Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost

(MedPage Today) -- CHICAGO--Randomized data suggest that an anti-angiogenic agent can kick-start immunotherapy's antitumor activity in non-small cell lung cancer (NSCLC) patients whose disease has already progressed after chemotherapy and a...